We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics

Download Mobile App





Clinical Trial to Study Effects of Steroid-Cannabidiol (CBD) Treatment on Hospitalized COVID-19 Patients

By HospiMedica International staff writers
Posted on 02 May 2020
Print article
Image: Rabin Medical Center (Photo courtesy of Wikimedia Commons).
Image: Rabin Medical Center (Photo courtesy of Wikimedia Commons).
A small-scale clinical trial is currently underway to evaluate the use of Cannabidiol (CBD) for the treatment of hospitalized patients with COVID-19 infection.

The clinical trial is being held by STERO Biotechs Ltd. (Bnei Brak, Israel), a clinical-stage company focused on CBD formulation research and development, in collaboration with Mor Research Applications, the Tech Transfer Office (TTO) of the largest Health Maintenance Organization (HMO) in Israel – Clalit. The small-scale clinical trial is being held at Rabin Medical Center Golda HaSharon Campus, treating 10 patients as a 'POC' with the aim of benefitting and helping hospitalized patients with COVID-19 infection.

Steroid treatment is usually the first or second line of treatment for hospitalized patients. CBD enhances the therapeutic effect of steroid treatment and treats the bio-mechanism affected by the virus. The initial study will evaluate the tolerability, safety, and efficacy of the CBD treatment, for hospitalized patients with COVID-19 infection. The treatment cycle will be for a few weeks with a subsequent follow-up period of the same length. Under Stero's allowed IP and pending the success of the 'POC', the company plans to scale up and expand to a phase 2a multi-center clinical trial, with an additional 40 hospitalized patients with COVID-19 infection, under FDA clinical trial guidelines and regulations.

“We estimate that our CBD-based treatment can enhance the current treatment of those patients who are in life-threatening conditions,” said David Bassa, Founder & CEO of Stero Biotechs. “Hospitalized COVID-19 patients are mostly being treated with steroids and our study is planned to demonstrate the benefit of a combined solution with steroid treatments. We are hopeful that this study will lead to faster benefit for the growing number of COVID-19 patients in Israel and around the world.”

Related Links:
STERO Biotechs Ltd.


Print article

Channels

Business

view channel
Illustration

Siemens to Acquire Varian Medical to Create Comprehensive Cancer Portfolio

Siemens Healthineers (Erlangen, Germany) has entered into an agreement to acquire Varian Medical Systems, Inc. (Palo Alto, CA, USA) that will lead to the creation of a global leader in healthcare with... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.